Biointron’s AbDrop™ & Cyagen’s HUGO-Ab™ is a high-throughput fully human antibody discovery platform that combines microdroplet-based single B cell screening with transgenic mice. This combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months.
Engineering Humanized Antibodies with Cyagen’s HUGO-Ab™ Mice
Cyagen’s HUGO-Ab™ mice are genetically engineered to produce fully humanized antibodies, setting them apart in the industry. By integrating human antibody variable gene libraries into mouse DNA using large-fragment genome knockin techniques, these mice retain critical regulatory elements and mouse constant regions. This advanced model allows for the production of highly developable antibodies with low immunogenicity, eliminating the need for subsequent humanization—a crucial step in cutting down development timelines.
Maximizing Efficiency with Biointron’s AbDrop™ Platform
Biointron’s AbDrop™ is a high-throughput microfluidic screening platform that can screen over 1 million plasma cells daily. By capturing naturally paired heavy and light chains from individual plasma cells, the platform identifies therapeutically relevant antibodies with unparalleled speed and accuracy.
Core Advantages:
Platform Capabilities: AbDrop™ is a microdroplet-based platform which can screen 1-2 million plasma cells daily, capturing hundreds of naturally paired heavy and light chains. This expedites the identification process of therapeutically relevant antibodies.
Microfluidic Technology: Microfluidic technology for antibody development involves manipulating small fluid volumes within microfabricated channels, offering precise control over experimental conditions and enabling high-throughput testing. This technology reduces reagent consumption, enhances reaction kinetics, and integrates multiple development steps into a single device, improving efficiency, speed, and precision in antibody production and screening.
Integration for Accelerated Discovery
Reduced Time-to-Market: By eliminating the need for post-discovery humanization and leveraging the speed of microfluidic screening, the time from discovery to clinical application is significantly reduced.
Robust Immune Responses: HUGO-Ab™ derived antibodies have demonstrated superior tumor inhibition in vivo, alongside potent immune activation. This has been validated through various functional assays, including T-cell activation and cytokine production studies.
In vivo studies using HUGO-Ab™ mice-derived antibodies have shown superior efficacy in inhibiting tumor growth, outperforming FDA-approved drugs like Tecentriq. This underscores the therapeutic potential of antibodies produced through this platform. Additionally, functional assays revealed robust immune responses, with HUGO-Ab™ antibodies displaying higher binding affinity and potency compared to current benchmarks.
Learn more about our High-throughput Fully Human Antibody Discovery Platform here.
